The global HIV response has made tremendous progress but is entering a new phase with
additional challenges. Scientific innovations have led to multiple safe, effective, and durable …

Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …

Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …

Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …

Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …

Antiretroviral therapy (ART) allows suppressed viremia to reach less than 50 copies/mL in
most treated persons living with HIV (PLWH). However, the existence of PLWH that show …

Background Antiretroviral therapy (ART) scale-up in sub-Saharan Africa combined with
weak routine virological monitoring has driven increasing HIV drug resistance. We …

In 2014, the Joint United Nations AIDS Programme established global targets such that 90%
of people living with HIV will be diagnosed, 90% of those diagnosed will be on antiretroviral …

A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …

Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …